VEGFA and breast carcinoma: The findings of this study demonstrate, despite a wide inter individual range of VEGF-A165b levels, statistically significant differences between healthy individuals and breast cancer patients and a change of VEGF-A165b levels over the course of cancer treatment to reach normal or above normal levels two years after finishing treatment.